Literature DB >> 27668394

The Predictive Value of Tumor Size, Volume, and Markers During Radiation Therapy in Patients With Cervical Cancer.

Kyu Chan Lee1, Hun Jung Kim, KiHoon Sung, Young Eun Choi, Seok Ho Lee, Soyi Lim, Kwang Beom Lee, Jin Woo Shin, Chan Yong Park, Young Saing Kim, Sun Jin Sym, Young Sup Shim, Seung Joon Choi.   

Abstract

OBJECTIVES: We investigated the prognostic significance of changes in primary tumor volume and serum squamous cell carcinoma antigen (SCC-ag) levels during radiation therapy (RT) in patients with cervical cancer.
METHODS: We conducted a review of 40 patients treated with RT. All patients received external beam RT and intracavitary brachytherapy. The primary tumor volume and squamous cell carcinoma antigen levels were measured pre-RT and mid-RT. Overall survival (OS) and progression free survival (PFS) were estimated, and possible prognostic factors for survival were analyzed.
RESULTS: The correlation coefficient between primary tumor volume reduction rate (pTVRR) and serum squamous cell carcinoma antigen reduction rate in all patients was 0.550 (P < 0.001). In univariate analysis, stage more than II (P <0.001), pre-RT pTV of 55 cm or more (P = 0.05), mid-RT tumor size of 4 cm or more (P = 0.004), and pTVRR of 90% or less (P = 0.031) were significant unfavorable prognostic factors for PFS, whereas stage (P = 0.009) was the only significant prognostic factor for OS. Multivariable analysis revealed that none of these factors were independently associated with PFS or OS.
CONCLUSIONS: There was a significant correlation between pTVRR and squamous cell carcinoma antigen reduction rate. Our findings indicate that the tumor parameters such as pre-RT pTV, mid-RT tumor size, and pTVRR are associated with PFS in women with cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27668394     DOI: 10.1097/IGC.0000000000000837

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  Strain elastography as an early predictor of long-term prognosis in patients with locally advanced cervical cancers treated with concurrent chemoradiotherapy.

Authors:  Yan Xu; Lijing Zhu; Li Zhu; Huanhuan Wang; Tong Ru; Baorui Liu; Jian He; Sibo Tian; Zhengyang Zhou; Xiaofeng Yang
Journal:  Eur Radiol       Date:  2019-07-29       Impact factor: 5.315

2.  Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis.

Authors:  Philip Junker; Julian Puppe; Fabinshy Thangarajah; Christian Domröse; Angela Cepic; Bernd Morgenstern; Dominik Ratiu; Martin Hellmich; Peter Mallmann; Marina Wirtz
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-08-20       Impact factor: 2.915

3.  Prognostic Role of Squamous Cell Carcinoma Antigen in Cervical Cancer: A Meta-analysis.

Authors:  Zhenhua Liu; Hongtai Shi
Journal:  Dis Markers       Date:  2019-06-02       Impact factor: 3.434

Review 4.  The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer.

Authors:  Jingxuan Fu; Weiping Wang; Yidan Wang; Chengeng Liu; Peichang Wang
Journal:  Radiat Oncol       Date:  2019-08-15       Impact factor: 3.481

5.  The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy.

Authors:  Heming Lu; Yuying Wu; Xu Liu; Huixian Huang; Hailan Jiang; Chaohua Zhu; Yuping Man; Pei Liu; Xianglong Li; Zhaohong Chen; Xianfeng Long; Qiang Pang; Shan Deng; Junzhao Gu
Journal:  Cancer Manag Res       Date:  2021-08-04       Impact factor: 3.989

6.  Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer.

Authors:  Wenjuan Chen; Siyi Xiu; Xingyun Xie; Huiming Guo; Yuanji Xu; Penggang Bai; Xiaoyi Xia
Journal:  Radiat Oncol       Date:  2022-01-10       Impact factor: 3.481

7.  The Prognostic Value of Tumor Size, Volume and Tumor Volume Reduction Rate During Concurrent Chemoradiotherapy in Patients With Cervical Cancer.

Authors:  Chang Sun; Shubin Wang; Wenjing Ye; RanLin Wang; Mingyu Tan; Hanyi Zhang; Jie Zhou; Minglun Li; Lichun Wei; Peng Xu; Guiquan Zhu; Jinyi Lang; Shun Lu
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

8.  Prognosis of stage III cervical cancer: a two-way outcome study.

Authors:  Huihui Zhou; Qi Li; Chunyan Xu; Hong Liang; Yanan Wang; Yani Duan; Min Song; Yaoxian Wang; Hong Jin; Tong Wang
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.